Study finds how fibrosis progresses in the human lung

As the researchers have discovered how the lung disease idiopathic pulmonary fibrosis (IPF) progresses, they will now be able to provide a method to discover new treatment targets for the disease. In the study, researchers examined differentially affected regions in the lungs obtained from individuals with IPF and found that what looks like normal lung is already undergoing changes in specific genes. Fifty per cent of patients with IPF will die in three to five years following diagnosis, and the cause of IPF is unknown. The two FDA-approved drugs to treat IPF slow the progress of the disease, but do not reverse it.